Treatment of Renal Cell Carcinoma with Lenvatinib and Everolimus
WO2021050219A1
Pharmaceutical composition for treating insomnia
WO2021003279A1
System for enhancing therapeutic compliance of the anti-cancer compound e7766
US2021002378A1
Anti-EphA4 antibody
WO2020242795A1
A method for treating cancer with an oral dosage form of an estrogen receptor-alpha inhibitor
WO2020230800A1
Method and compound useful in preparation of orexin-2 receptor antagonist, and lemborexant having few impurities
WO2020218460A1
Diagnostic assistance device, speculation device, diagnostic assistance system, diagnostic assistance method, diagnostic assistance program, and learned model
WO2020218232A1
Biomarker for treating rheumatoid arthritis
US2021023047A1
Pharmaceutical composition for treating tumor
TW202100528A
Pentacyclic heterocyclic compound
TW202100531A
Salt of pentacyclic compound and crystals thereof
WO2020179712A1
Methods for predicting tumor response to eribulin
WO2020146568A1
Method for synthesis of diazabicyclo[6.2.0]decane related compounds
WO2020124090A1
Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds
WO2020129826A1
Formulation comprising liposomes
CA3114931A1
Herboxidiene splicing modulator antibody-drug conjugates and methods of use
WO2021075061A1
Cognitive function measurement device, cognitive function measurement system, cognitive function measurement method, and cognitive function measurement program
WO2020071457A1
Biomarkers for a combination therapy comprising lenvatinib and everolimus
WO2020071451A1
Biomarkers for a therapy comprising a sorafenib compound
